country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P99024

Copy Link Print Information

Biologically Validated

Glofitamab

(Synonyms: RO7082859; RG-6026)

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL).

For research use only. We do not sell to patients.

Purity: 99.12%
CAS No.: 2229047-91-8
Molecular Weight:194 kDa

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Glofitamab Chemical Structure

CAS No.: 2229047-91-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biological Activity
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Application
- Verified Bioactivity
Chemical Information
Publications (1)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Isotype

IgG1-kappa/lambda with domain crossover, trivalent

Recommend Isotype Controls

Human IgG1 (L234A/L235A) kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

CD3E & MS4A1

In Vitro

Glofitamab (0.1 µg/mL, 48 h) stimulates the expression of 4-1BB (CD137) on CD8+ tumor-infiltrating lymphocyte (TILs) in the lymphoma tumor microenvironment (TMEs) and augmented diffuse large B cell lymphoma (DLBCL) cell death combined with either FAP-IL2v (HY-P99902) or FAP-4-1BBL^[4].
Glofitamab (0.2-200 ng/mL, 16 h)-mediated DLBCL cell killing requires the formation of stable T effector cell-tumor cell synapses^[5].
Glofitamab has no effect on the transient reduction in T-lymphocyte subsets, NK cells and monocytes by Obinutuzumab (HY-P9910) pretreatment (Gpt)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Glofitamab (0.3-100 μg/kg, i.v., a single dose) induces a dose-dependent increase in cytokine levels (IL-1Ra, IL-2, IL-5, IL-6, IL-8, IL-10, G-CSF, IFN-γ and TNF-α) in Cynomolgus Monkeys^[3].
Glofitamab (0.5 mg/kg, i.v., a single dose) induces early and lasting T cell engagement and activity in mice^[5].

Pharmacokinetic parameters of Glofitamab (i.v., a single dose) in cynomolgus monkeys with or without Obinutuzumab (Gpt: 50 mg/kg) (MeSt: Mechanistic Study; MTD: Maximum Tolerated Dose)^[3]

Study	Gpt	Dose (μg/kg)	CL(mL/day/kg)	V_c(mL/kg)	T_1/2 (days)	C_max (μg/mL)	AUC_last/dose(h·μg/mL/μg/kg)
MTD	No	0.3	nd	nd	nd	0.00374/0.00663	nd
MTD	No	1	nd	45.6/nd	nd	0.0188/nd	0.0162/nd
MTD	No	3	864/920	35.8/31.9	0.218/0.180	0.0704/0.0798	0.0218/0.0234
MTD	No	10	735/656	26.7/24.6	0.143/0.159	0.318/0.354	0.0290/0.0339
MTD	No	30	600/653	27.9/36.1	0.173/0.151	0.958/0.759	0.0397/0.0335
MTD	No	100	190/290	34.9/41.6	0.203/0.113	2.74/2.29	0.126/0.0826
MeSt	No	100	384±106	43.2±7.26	0.314±0.158	2.22±0.384	0.0679±0.0246
MeSt	Yes	100	81.7±18.3	41.1±5.59	2.82±0.959	2.56±0.320	0.308±0.0773

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Cynomolgus Monkeys^[3]
Dosage:

0.3-100 μg/kg
Administration:

i.v., a single dose, collected samples for cytokine measurements predose, 4, 24, 96 and 168 h post-dosing
Result:

Resulted in cytokine levels peaked at 4 h post dose, with levels returning to baseline after 96 h for most cytokines in Cynomolgus Monkeys.

Animal Model:

NSG mice co-injected with WSU and DLCL2 tumor cells and HSC-NSG-derived T cells^[5]
Dosage:

0.5 mg/kg
Administration:

i.v., a single dose, imaged 24, 48 or 72 hours post treatment
Result:

Resulted in a higher frequency and longer duration of T cell-tumor cell interactions in mice, not only at early, but also at late time points.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

916 [NCBI] & 931 [NCBI]

Accession

P07766 & P11836

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

IgG1-kappa/lambda with domain crossover, trivalent

Application

ELISA, FACS, Functional assay

Verified Bioactivity

Flow cytometry analysis of Jurkat cells labelling CD3 with Glofitamab at 200 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
Flow cytometry analysis of Raji cells labelling CD20 with Glofitamab at 20 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).

Chemical Information

CAS No. 2229047-91-8
Appearance Liquid
Molecular Weight 194 kDa
Color Colorless to light yellow
SMILES

[Glofitamab]
Synonyms

RO7082859; RG-6026
Shipping

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (1)

All

Sort by:

Journal Impact Factor

MAbs

Optimizing human FcRn mouse models to improve pharmacokinetic evaluation of antibody drug candidates. [Abstract]

2026 Dec 31;18(1):2649990. PMID: 41878863

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (268 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

References

[1]. Hutchings M, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021;39(18):1959-1970. [Content Brief]

[2]. Bröske AE, et al. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. Blood Adv. 2022;6(3):1025-1037. [Content Brief]

[3]. Frances N, et al. Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab. J Pharm Sci. 2022 Apr;111(4):1208-1218. [Content Brief]

[4]. Apollonio B, et al. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma. J Clin Invest. 2023 Jul 3;133(13):e166070. [Content Brief]

[5]. Cremasco F, et al. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model. PLoS One. 2021 Jan 6;16(1):e0241091. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Application
- Biological Activity
Chemical Information
Publications (1)
Purity & Documentation
References

1/16

IgG1-kappa/lambda with domain crossover, trivalent
1/16

Flow cytometry analysis of Jurkat cells labelling CD3 with Glofitamab at 200 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
1/16

Flow cytometry analysis of Raji cells labelling CD20 with Glofitamab at 20 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
1/16

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Glofitamab

Antibody Inhibitor Library

Publications Citing Use of MedChemExpress (MCE) Glofitamab

Biological Activity

Chemical Information

Publications (1)

Purity & Documentation

References

Calculators

Help & FAQs

Glofitamab

Cell-ATP Viability Detection Kit

Protein A Agarose

HOLO Human Interleukin-2 (IL-2) Detection Kit

Bradford Protein Assay Kit

Cytotoxicity LDH Assay Kit

PBS Buffer (1×)

DPBS Buffer (1×)

Antibody Inhibitor Library

Publications Citing Use of MedChemExpress (MCE) Glofitamab

Biological Activity

Chemical Information

Publications (1)

Purity & Documentation

References

Calculators

Help & FAQs

Glofitamab Related Classifications

HY-P99024 Related Classifications